The Journal of Urology
Volume 183, Issue 4 , Pages 1598-1603 , April 2010

Screening Agents for Preventive Efficacy in a Bladder Cancer Model: Study Design, End Points, and Gefitinib and Naproxen Efficacy

Received 26 May 2009

References 

  1. Lippman SM, Klein EA, Goodman , et al. Effect of selenium and vitamin E on risk of prostate cancer and other cancers: the selenium and vitamin E cancer prevention trial. JAMA. 2009;301:39
  2. Vogel VG, Costantino JP, Wickerham DL, et al. Effects of tamoxifen vs raloxifene on the risk of developing invasive breast cancer and other disease outcomes: the NSABP Study of Tamoxifen and Raloxifene (Star) P-2 Trial. JAMA. 2006;295:2727
  3. Fabian CJ, Kimler BF, Zalles CM, et al. Reduction in proliferation with six months of letrozole in women on hormone replacement therapy. Breast Cancer Res Treatment. 2007;106:75
  4. Dowsett M, Smith IE, Ebbs SR, et al. Prognostic value of Ki67 expression after short-term presurgical endocrine therapy for primary breast cancer. J Natl Cancer Inst. 2007;99:167
  5. Arpino G, Laucirica R, Elledge RM. Premalignant and in situ breast disease: biology and clinical implications. Ann Intern Med. 2005;143:446
  6. Haag JD, Brasic GM, Shepel LA, et al. A comparative analysis of allelic imbalance events in chemically induced rat mammary, colon and bladder tumors. Mol Carcinog. 1999;24:47
  7. Tsao JL, Yalabe Y, Salovaara R, et al. Genetic reconstruction of individual colorectal tumor histories. Proc Natl Acad Sci U S A. 2000;97:1236
  8. Beerenwinkel N, Antal T, Dingli D, et al. Genetic progression and the waiting time to. cancer. PLos Comput Biol. 2007;3:e225
  9. Kelloff GJ, Lippman SM, Dannenberg AD, et al. Progress in chemoprevention drug development: the promise of molecular biomarkers for prevention of intraepithelial neoplasia and cancer—a plan to move forward. Clin Cancer Res. 2006;12:3661
  10. Grubbs CJ, Moon RC, Squire RA, et al. 13-Cis-retinoic acid: inhibition of bladder carcinogenesis induced in rats by N-butyl-N-(4-hydroxybutyl)nitrosamine. Science. 1997;198:743
  11. Grubbs CJ, Lubet RA, Koki AT, et al. Celecoxib inhibits N-butyl-N-(4 hydroxy)-nitrosamine-induced urinary bladder cancers in male B6D2F1 mice and female Fischer-344 rats. Cancer Res. 2000;60:5597
  12. Forreste JC, Ury HK. The signed rank (Wilcoxon) test in the rapid analysis of biological data. Lancet. 1969;1:239
  13. Bertagnolli MM, Eagle CJ, Zauber AG, et al. Celecoxib for the prevention of sporadic colorectal adenomas. N Engl J Med. 2006;355:873
  14. Meyskens FL, Mclaren CE, Pelot D, et al. Difluoromethylornithine plus sulindac for the prevention of sporadic colorectal adenomas: a randomized placebo-controlled, double-blind trial. Cancer Prev Res. 2008;1:32
  15. Lubet RA, Huebner K, Fong LY, et al. 4-Hydroxybutyl(butyl)nitrosamine-induced urinary bladder cancers in mice: characterization of FHIT and surviving expression and chemopreventive effects of indomethacin. Carcinogenesis. 2005;26:571
  16. Yao R, Yiun Y, Grubbs CJ, et al. Gene expression profiling of chemically induced rat bladder tumors. Neoplasia. 2007;9:207
  17. Williams PD, Lee JK, Theodorescu D. Molecular credentialing of rodent bladder carcinogenesis models. Neoplasia. 2008;10:838
  18. Lubet RA, Yang CS, Lee MJ, et al. Preventive effects of polyphenone E on urinary bladder and mammary cancers in rats and collections with serum and urine levels of tea polyphenols. Mol Cancer Ther. 2007;6:2022
  19. Lubet RA, Fischer SM, Steele VE, et al. Rosiglitazone, a PPAR gamma agonist: potent promoter of hydroxybutyl(butyl)nitrosamine induced urinary bladder cancers. Int J Cancer. 2008;123:2254
  20. Lubet RA, Steele VE, Julianna MM et al: Chemopreventive effects of the EGFr inhibitor Iressa on chemically (OH-BBN) induced urinary bladder cancers: histopathologic and biochemical endpoints. Presented at American Association for Cancer Research-National Cancer Institute-European Organisation for Research and Treatment of Cancer Conference on Molecular Targets and Therapeutics, San Francisco, California, October 22–26, 2007, p 7.
  21. Li H, Schut HA, Conran P, Kramer PM, et al. Prevention by aspirin and its combination with alpha-difluoromethylornithine of agony methane-induced tumors aberrant crypt foci and prostaglandin E2 levels in rat colon. Carcinogenesis. 1999;20:425
  22. Flossman E, Rothwell PM. Aspirin Trial and the UK-TIA Aspirin Trial (Effect of aspirin on long term risk of colorectal cancer, consistent evidence from randomized and observational studies). Lancet. 2007;369:1577
  23. Gee JR, Jarred DF, Bruskewitz RC, et al. Reduced bladder cancer recurrence rate with cardio protective aspirin after intravesical bacille Calmette-Guerin. BJU Int. 2008;103:736
  24. Baur JA, Sinclair DA. Therapeutic potential of resveratrol the in vivo evidence. Nat Rev Drug Discov. 2005;5:493
  25. Boocock DJ, Faust GE, Patel , et al. Phase I dose escalation pharmacokinetic study in healthy volunteers of resveratrol, a potential cancer chemopreventive agent. Cancer Epidemiol Biomarkers Prev. 2007;16:1246
  26. Reddy BS, Hirose Y, Lubet R, et al. Chemoprevention of colon cancer by specific cyclooxygenase-2 inhibitor, celecoxib, administered during different stages of carcinogenesis. Cancer Res. 2000;60:293
  27. Li H, Kramer PM, Lubet RA, Steele , et al. Termination of piroxicam treatment and the occurrence of azoxymethane-induced colon cancer in rats. Cancer Lett. 1999;147:187
  28. Wang Y, Zhangqui Z, Kastens E, et al. Mice with alterations in both p53 and Ink4a/Arf display a striking increase in lung tumor multiplicity and progression: differential chemopreventive effect of budesonide in wild type and mutant A/J mice. Cancer Res. 2003;63:4389
  29. Fosbol EL, Gislason GH, Jacobsen S, et al. Risk of myocardial infarction and death associated with the use of nonsteroidal anti-inflammatory drugs (NSAIDs) among healthy individuals: a nationwide cohort study. Clin Pharmacol Ther. 2009;85:190
  30. Chan FK, Abraham NS, Scheiman JM, et al. Management of patients on nonsteroidal anti inflammatory drugs: a clinical practice recommendation from the First International Working Party on Gastrointestinal and Cardiovascular Effects of Nonsteroidal Anti-inflammatory Drugs and Anti-platelet Agents. Am J Gastroenterol. 2008;103:2908

 Study received institutional animal care and use committee approval.

 Supported by National Cancer Institute Contract HHSN261200433001C.

PII: S0022-5347(09)03145-0

doi: 10.1016/j.juro.2009.12.001

The Journal of Urology
Volume 183, Issue 4 , Pages 1598-1603 , April 2010

Article Tools

* Image Usage & Resolution